These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 37240080)

  • 41. Emerging sodium-glucose cotransporter-2 inhibitor therapies for managing heart failure in patients with chronic kidney disease.
    Chan JSK; Perone F; Bayatpoor Y; Tse G; Harky A
    Expert Opin Pharmacother; 2023 Jun; 24(8):935-945. PubMed ID: 37070470
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictors of cardio-kidney complications and treatment failure in patients with chronic kidney disease and type 2 diabetes treated with SGLT2 inhibitors.
    Kovesdy C; Schmedt N; Folkerts K; Bowrin K; Raad H; Batech M; Fried L
    BMC Med; 2022 Jan; 20(1):2. PubMed ID: 35000594
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Furtado RHM; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Circulation; 2019 Apr; 139(17):2022-2031. PubMed ID: 30786725
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S; Zhao L; Mi Y; He W
    Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
    Zelniker TA; Wiviott SD; Raz I; Im K; Goodrich EL; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Furtado RHM; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Sabatine MS
    Lancet; 2019 Jan; 393(10166):31-39. PubMed ID: 30424892
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sodium-glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus.
    Scheen AJ
    Nat Rev Endocrinol; 2020 Oct; 16(10):556-577. PubMed ID: 32855502
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Performance of sodium-glucose cotransporter 2 inhibitors in cardiovascular disease.
    Khater J; Malakouti S; Khoury AE; Cortese B
    J Cardiovasc Med (Hagerstown); 2024 Apr; 25(4):247-258. PubMed ID: 38305141
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Analysis from the EMPA-REG OUTCOME
    Mayer GJ; Wanner C; Weir MR; Inzucchi SE; Koitka-Weber A; Hantel S; von Eynatten M; Zinman B; Cherney DZI
    Kidney Int; 2019 Aug; 96(2):489-504. PubMed ID: 31142441
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
    Wheeler DC; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Toto RD; Sjöström CD; Langkilde AM; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Jan; 9(1):22-31. PubMed ID: 33338413
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure.
    Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N
    Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914
    [No Abstract]   [Full Text] [Related]  

  • 51. Dapagliflozin in Patients with Chronic Kidney Disease.
    Heerspink HJL; Stefánsson BV; Correa-Rotter R; Chertow GM; Greene T; Hou FF; Mann JFE; McMurray JJV; Lindberg M; Rossing P; Sjöström CD; Toto RD; Langkilde AM; Wheeler DC;
    N Engl J Med; 2020 Oct; 383(15):1436-1446. PubMed ID: 32970396
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes-cardiovascular and renal benefits in patients with chronic kidney disease.
    Milder TY; Stocker SL; Samocha-Bonet D; Day RO; Greenfield JR
    Eur J Clin Pharmacol; 2019 Nov; 75(11):1481-1490. PubMed ID: 31377891
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Can chronic kidney disease lead to chronic heart failure, and does worsening chronic heart failure lead to chronic kidney disease progression.
    Leon SJ; Tangri N
    Curr Opin Nephrol Hypertens; 2022 Mar; 31(2):205-211. PubMed ID: 34954720
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future?
    Neuen BL; Jardine MJ; Perkovic V
    Nephrol Dial Transplant; 2020 Jan; 35(Suppl 1):i48-i55. PubMed ID: 32003833
    [TBL] [Abstract][Full Text] [Related]  

  • 55. SGLT2 inhibitors for the composite of cardiorenal outcome in patients with chronic kidney disease: A systematic review and meta-analysis of randomized controlled trials.
    Chen HB; Yang YL; Yu TH; Li YH
    Eur J Pharmacol; 2022 Dec; 936():175354. PubMed ID: 36306924
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
    Woo V; Connelly K; Lin P; McFarlane P
    Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
    [No Abstract]   [Full Text] [Related]  

  • 57. When and How to Use Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction or Chronic Kidney Disease.
    O'Meara E; Verma S
    Can J Cardiol; 2021 Apr; 37(4):669-673. PubMed ID: 33450364
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [SGLT2 inhibitors in patients with chronic kidney disease : from clinical trials to guidelines and new prospects for clinical practice].
    Scheen AJ; Delanaye P
    Rev Med Liege; 2021 Mar; 76(3):186-194. PubMed ID: 33682388
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cardiorenal disease management in type 2 diabetes: An expert consensus.
    Mohan V; Singh AK; Zargar AH; Almeida A; Bhalla AK; Mohan JC; Dalal J; Sahay M; Mohanan PP; Maitra S; Ghosh S; Jeloka T; Kaul U; Sakhuja V; Das MK
    Diabetes Metab Syndr; 2022 Dec; 16(12):102661. PubMed ID: 36375366
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and cardiac arrhythmias: a systematic review and meta-analysis.
    Li HL; Lip GYH; Feng Q; Fei Y; Tse YK; Wu MZ; Ren QW; Tse HF; Cheung BY; Yiu KH
    Cardiovasc Diabetol; 2021 May; 20(1):100. PubMed ID: 33962654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.